Table 2.
The number of cases that showed differences in variables before and after dry eye treatment
| TBUT (n) | HOAs (n) | Power of astigmatism* (n) | Axis of astigmatism* (n) | |
|---|---|---|---|---|
| Group R (n = 30) | ||||
| Difference** = 0 | 1 | 0 | 0 | 1 |
| Difference** < 0 | 29 | 3 | 1 | 1 |
| Difference** > 0 | 0 | 27 | 29 | 28 |
| P value (Wilcoxon signed-rank test) | 2.56 × 10−6 | 3.69 × 10−6 | 2.35 × 10−6 | 3.34 × 10−6 |
| Group M (n = 28) | ||||
| Difference** = 0 | 23 | 3 | 4 | 7 |
| Difference** < 0 | 4 | 7 | 7 | 10 |
| Difference** > 0 | 1 | 18 | 17 | 11 |
| P value (Wilcoxon signed-rank test) | 0.178 | 0.054 | 0.005 | 0.543 |
Wilcoxon signed-rank test: comparison of the number of cases that showed differences in the four variables, before and after dry eye treatment
Group R 2% rebamipide ophthalmic suspension, Group M Mytear® ophthalmic solution, TBUT tear breakup time, HOAs higher-order aberrations; n = cases
**Difference indicates the absolute difference in the variables before and after dry eye treatment